Endurance RP

Endurance RP (now Regent Pacific Group) is a Hong Kong-based investment holding company specializing in healthcare, wellness, and life sciences. Its core pharmaceutical asset is Fortacin, a topical spray for premature ejaculation that is approved in the European Union and undergoing Phase 3 trials in the United States. The company also owns Deep Longevity, an AI-focused subsidiary that develops biological "aging clocks" to track human aging and provide personalized longevity interventions. Endurance RP leverages a global network of partnerships, including agreements with Recordati and Fosun Pharma, to commercialize its products across Europe, Asia, and the Middle East. The firm is strategically positioned to capitalize on the growing longevity economy and unmet needs in urological health.